References
- Zouboulis CC, Bechara FG, Dickinson-Blok JL, et al. Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization –systematic review and recommendations from the HS ALLIANCE working group. J Eur Acad Dermatol Venereol. 2019;33(1):19–31.
- Mendes-Bastos P, Martorell A, Magina S. Ertapenem for the treatment of hidradenitis suppurativa: how much do we need it? Actas Dermosifiliogr. 2018;109(7):582–583.
- Join-Lambert O, Coignard-Biehler H, Jais JP, et al. Efficacy of ertapenem in severe hidradenitis suppurativa: a pilot study in a cohort of 30 consecutive patients. J Antimicrob Chemother. 2016;71(2):513–520.
- Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian hidradenitis suppurativa foundations: part II: topical, intralesional, and systemic medical management. J Am Acad Dermatol. 2019;81(1):91–101.
- Braunberger TL, Nartker NT, Nicholson CL, et al. Ertapenem - a potent treatment for clinical and quality of life improvement in patients with hidradenitis suppurativa. Int J Dermatol. 2018;57(9):1088–1093.
- Musson DG, Majumdar A, Birk K, et al. Pharmacokinetics of intramuscularly administered ertapenem. Antimicrob Agents Chemother. 2003;47(5):1732–1735.